Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
Anker MS, Potthoff SK, Lena A, Porthun J, Hadzibegovic S, Evertz R, Denecke C, Fröhlich AK, Sonntag F, Regitz-Zagrosek V, Rosen SD, Lyon AR, Lüscher TF, Spertus JA, Anker SD, Karakas M, Bullinger L, Keller U, Landmesser U, Butler J, von Haehling S. Anker MS, et al. Among authors: butler j. Eur J Heart Fail. 2023 Sep;25(9):1635-1647. doi: 10.1002/ejhf.2951. Epub 2023 Aug 22. Eur J Heart Fail. 2023. PMID: 37369985
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators. Anker SD, et al. Among authors: butler j. Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16. Eur J Heart Fail. 2019. PMID: 31523904 Free article.
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
Anker SD, Butler J, Usman MS, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Rocca HPB, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, González-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Iwata T, Schnee JM, Brueckmann M, Pocock SJ, Zannad F. Anker SD, et al. Among authors: butler j. Nat Med. 2022 Dec;28(12):2512-2520. doi: 10.1038/s41591-022-02041-5. Epub 2022 Dec 5. Nat Med. 2022. PMID: 36471037 Free PMC article. Clinical Trial.
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial.
Carson P, Teerlink JR, Komajda M, Anand I, Anker SD, Butler J, Doehner W, Ferreira JP, Filippatos G, Haass M, Miller A, Pehrson S, Pocock SJ, Schnaidt S, Schnee JM, Zannad F, Packer M. Carson P, et al. Among authors: butler j. JACC Heart Fail. 2023 Apr;11(4):407-417. doi: 10.1016/j.jchf.2022.11.017. Epub 2023 Feb 1. JACC Heart Fail. 2023. PMID: 36881400 Free article.
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
Filippatos G, Farmakis D, Butler J, Zannad F, Ferreira JP, Ofstad AP, Iwata T, Brueckmann M, Pocock SJ, Packer M, Anker SD; EMPEROR-Preserved Trial Committees and Investigators. Filippatos G, et al. Among authors: butler j. Eur J Heart Fail. 2023 Jul;25(7):970-977. doi: 10.1002/ejhf.2861. Epub 2023 May 8. Eur J Heart Fail. 2023. PMID: 37062866 Clinical Trial.
6,125 results